Vir Biotechnology Q2 net loss narrows to $111.0 million; revenue falls to $1.2 million
Vir Biotechnology reported second-quarter 2025 results, with a net loss of $111.0 million, or $0.80 per share, compared with $138.4 million, or $1.02 per share, a year earlier. Revenue fell to $1.2 million from $3.1 million, and cash, cash equivalents and investments were $892.1 million at June 30, 2025, which the company says funds operations into mid-2027.
Key points
- Net loss was $111.0 million ($0.80 per share) versus $138.4 million ($1.02 per share) in Q2 2024.
- Total revenues were $1.2 million versus $3.1 million in Q2 2024.
- Cash, cash equivalents and investments were $892.1 million at June 30, 2025, down about $127.7 million in the quarter, including $50.5 million of ECLIPSE milestone payments.
- R&D expenses were $97.5 million versus $105.1 million, reflecting restructuring savings; the ECLIPSE registrational program in chronic hepatitis delta is fully underway.
The filing
Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.